Story
Aspen Neuroscience, Bambusa Therapeutics Each Target Up to $159.5M in IPOs Amid Biotech Listing Trend

Aspen Neuroscience and Bambusa Therapeutics on Monday launched their U.S. initial public offering roadshows, continuing a steady stream of biotech listings in an otherwise quiet market. Both clinical-stage drug developers are seeking to capitalize on investor demand for companies with specific clinical catalysts.
Offering Details
Both companies are marketing their offerings with identical terms, according to filings. A successful IPO at the top of the range would provide significant funding for their respective clinical trials.
- Shares Offered: Each company plans to sell 9.38 million shares.
- Price Range: The shares are being marketed at a price between $15 and $17 apiece.
- Potential Proceeds: At the high end of the range, each IPO could raise up to $159.5 million.
Aspen Neuroscience will trade on the Nasdaq under the ticker symbol "ASPE," while Bambusa Therapeutics will list under "BBTX."
Biotech Defies IPO Slowdown
The biotech sector has been a notable bright spot in a fall IPO window marked by market choppiness and rising borrowing costs, which have deterred issuers from other industries. According to a Reuters report, more than half a dozen biotech firms have gone public in New York since September.
AdLukas Muehlbauer, an associate at IPOX, told Reuters that the sector's appeal lies in its potential for returns based on clinical developments, which can be independent of the broader economic climate. "Biotech offers investors opportunities where clinical catalysts can drive returns even when the broader economic outlook is uncertain," Muehlbauer said.
However, Muehlbauer also noted that investor appetite remains selective, with higher financing costs presenting a challenge for companies that are years away from generating revenue.
Company Pipelines
Aspen Neuroscience, based in San Diego, California, is focused on developing therapies for neurodegenerative conditions. Its lead product candidate, sasineprocel, is in an early-to-mid-stage clinical trial for treating Parkinson’s disease.
Bambusa Therapeutics, based in Boston, Massachusetts, develops drugs for immunological and inflammatory disorders. Its primary candidate, BBT001, is in early-stage development to treat a form of dermatitis and other inflammatory skin diseases.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.